GlassScriptPhysician profile
John Richard Born
NPI 1225063357
$9,053.24
in general payments reported to CMS, 2019-2025
45 companies · $1,212 in 2025
The $1,212 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,207 · 2020: $1,341 · 2021: $1,352 · 2022: $1,211 · 2023: $1,321 · 2024: $1,409 · 2025: $1,212.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,927 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,926.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,062.99 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $982.34 | 2020-2025 | Ubrelvy, Vraylar, Qulipta |
| Astrazeneca Pharmaceuticals LP | $775.62 | 2019-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $693.66 | 2019-2025 | Mounjaro, Amyvid, Zepbound |
| Amgen INC. | $685.64 | 2019-2025 | Otezla, Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $667.10 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $553.05 | 2019-2025 | Spravato, Xarelto |
| Glaxosmithkline, LLC. | $475.24 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $400.55 | 2019-2025 | |
| Amarin Pharma, INC. | $267.71 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $227.46 | 2020-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $225.85 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $213.17 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $180.48 | 2019-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $146.58 | 2019-2024 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Born listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.